UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of (I.R.S. Em ...

General Corporate & Gene Therapy Overview: At the Forefront of the Human Genome Medicine Revolution May 2021 General Corporate & Gene Therapy Overview Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential reg ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2021 Earnings Conference Call May 10, 2021 8:30 AM ET Company Participants Andrew Faughnan - Head, IR John Crowley - Chairman and CEO Bradley Campbell - President and COO Daphne Quimi - CFO Jeff Castelli - Chief Development Officer Mitchell Goldman - SVP, Clinical Research Conference Call Participants Ritu Baral - Cowen & Company Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Tessa Romero - JPMorgan Salveen Richter - Goldman Sachs Mohit Bansal - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2021 OR (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Juris ...

General Corporate & Gene Therapy Overview: At the Forefront of the Human Genome Medicine Revolution April 2021 General Corporate & Gene Therapy Overview Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential r ...

N-140N-233N-390N-470N-652N-882N-925 rhGAA – kif + Endo H IHC : LC3 II B. 0 1 2 3 4 0 20 40 60 80 100 120 Time (Hours) Normalized GAA Activity(%) Stability in buffer (pH 7.4) 0 1 2 3 4 0 20 40 60 80 100 120 Cipaglucosidase alfa Cipaglucosidase alfa + 17 µM miglustat Cipaglucosidase alfa + 170 µM miglustat Stability in human blood Time (Hours) Normalized GAA Activity(%) Enhancing Delivery of Acid Alpha-Glucosidase (GAA) to Skeletal Muscle in Pompe Disease (PD): Key Challenges and Attributes of AT-GAA Nithya S ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2020 Earnings Conference Call March 1, 2021 8:30 AM ET Company Participants Andrew Faughnan - Head, IR John Crowley - Chairman & CEO Bradley Campbell - President & COO Jeff Castelli - CDO Daphne Quimi - CFO Hung Do - Chief Science Officer Mitchell Goldman - SVP, Clinical Research Conference Call Participants Tazeen Ahmad - Bank of America Irina Margine - Cowen Tessa Romero - JP Morgan Mohit Bansal - Citigroup Kristen Kluska - Cantor Fitzgerald Aaron Welch - Guggenh ...

Full Year 2020 Financial Results Conference Call & Webcast March 1, 2021 Introduction Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization pla ...

Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of (I.R.S. Employ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other J ...